Free Trial
→ 3..2..1.. AI 2.0 ignition (don’t sleep on this) (From Timothy Sykes) (Ad) Buy PHAT Stock  Free PHAT Stock Alerts

Phathom Pharmaceuticals (PHAT) Financials

Phathom Pharmaceuticals logo
$9.74 +0.19 (+1.99%)
Closing price 04:00 PM Eastern
Extended Trading
$9.66 -0.08 (-0.86%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Phathom Pharmaceuticals

Annual Income Statements for Phathom Pharmaceuticals

This table shows Phathom Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -255 -129 -144 -198 -202 -334
Consolidated Net Income / (Loss)		 -255 -129 -144 -198 -202 -334
Net Income / (Loss) Continuing Operations		 -255 -129 -144 -198 -202 -334
Total Pre-Tax Income 		-255 -129 -144 -198 -202 -334
Total Operating Income		 -106 -126 -135 -172 -167 -277
Total Gross Profit		 0.00 0.00 0.00 0.00 0.52 47
Total Revenue		 0.00 0.00 0.00 0.00 0.68 55
Operating Revenue		 - - - 0.00 0.68 55
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.17 7.97
Operating Cost of Revenue		 - - - 0.00 0.17 7.97
Total Operating Expenses		 106 126 135 172 168 325
Selling, General & Admin Expense		 6.94 28 63 101 118 291
Research & Development Expense		 99 98 72 71 50 34
Total Other Income / (Expense), net		 -149 -3.40 -8.80 -25 -34 -57
Interest Expense		 4.18 4.58 6.79 27 42 72
Interest & Investment Income		 1.09 1.09 0.04 2.13 7.88 15
Other Income / (Expense), net		 -146 0.09 -2.06 -0.11 -0.19 -0.01
Basic Earnings per Share		 ($22.45) ($3.88) ($3.89) ($5.05) ($3.93) ($5.29)
Weighted Average Basic Shares Outstanding		 11.37M 33.23M 37.00M 39.12M 51.29M 63.18M
Diluted Earnings per Share		 ($22.45) ($3.88) ($3.89) ($5.05) ($3.93) ($5.29)
Weighted Average Diluted Shares Outstanding		 11.37M 33.23M 37.00M 39.12M 51.29M 63.18M
Weighted Average Basic & Diluted Shares Outstanding		 11.37M 33.23M 37.00M 41.97M 58.48M 69.64M

Quarterly Income Statements for Phathom Pharmaceuticals

This table shows Phathom Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74 -94
Consolidated Net Income / (Loss)		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74 -94
Net Income / (Loss) Continuing Operations		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74 -94
Total Pre-Tax Income 		-51 -55 -38 -41 -43 -80 -83 -91 -86 -74 -94
Total Operating Income		 -43 -47 -30 -32 -36 -70 -70 -77 -71 -59 -79
Total Gross Profit		 0.00 - 0.00 0.00 0.00 0.52 1.49 5.95 14 26 25
Total Revenue		 0.00 - 0.00 0.00 0.00 0.68 1.91 7.32 16 30 29
Operating Revenue		 - - 0.00 0.00 0.00 0.68 1.91 7.32 16 30 29
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 0.17 0.43 1.38 2.36 3.82 3.72
Operating Cost of Revenue		 - - 0.00 0.00 0.00 0.17 0.43 1.38 2.36 3.82 3.72
Total Operating Expenses		 43 47 30 32 36 70 71 83 85 85 104
Selling, General & Admin Expense		 24 31 19 19 23 57 62 76 76 77 94
Research & Development Expense		 19 16 11 13 12 13 9.43 7.38 8.69 8.58 9.18
Total Other Income / (Expense), net		 -8.56 -8.41 -7.74 -9.26 -7.58 -9.70 -13 -14 -15 -15 -15
Interest Expense		 9.28 9.60 9.22 9.62 10 13 17 18 18 19 18
Interest & Investment Income		 0.73 1.29 1.46 0.35 2.72 3.35 4.31 3.62 3.71 3.51 2.64
Other Income / (Expense), net		 -0.01 -0.09 0.02 0.00 -0.20 -0.01 -0.04 -0.01 -0.01 0.05 -0.02
Basic Earnings per Share		 ($1.32) ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99) ($1.31)
Weighted Average Basic Shares Outstanding		 38.82M 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M 71.97M
Diluted Earnings per Share		 ($1.32) ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99) ($1.31)
Weighted Average Diluted Shares Outstanding		 38.82M 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M 71.97M
Weighted Average Basic & Diluted Shares Outstanding		 41.62M 41.97M 43.61M 56.80M 57.25M 58.48M 58.54M 59.59M 68.38M 69.64M 69.81M

Annual Cash Flow Statements for Phathom Pharmaceuticals

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 243 44 -104 -28 228 -84
Net Cash From Operating Activities		 -37 -70 -148 -147 -138 -267
Net Cash From Continuing Operating Activities		 -37 -70 -148 -147 -138 -267
Net Income / (Loss) Continuing Operations		 -255 -129 -144 -198 -202 -334
Consolidated Net Income / (Loss)		 -255 -129 -144 -198 -202 -334
Depreciation Expense		 0.01 0.32 0.52 0.62 0.58 0.80
Amortization Expense		 0.41 1.27 3.60 2.11 1.88 2.19
Non-Cash Adjustments To Reconcile Net Income		 228 26 0.13 41 75 80
Changes in Operating Assets and Liabilities, net		 -9.57 32 -8.82 7.08 -14 -15
Net Cash From Investing Activities		 -25 -1.04 -0.33 -1.04 -1.63 -0.14
Net Cash From Continuing Investing Activities		 -25 -1.04 -0.33 -1.04 -1.63 -0.14
Purchase of Property, Plant & Equipment		 -0.13 -1.04 -0.33 -1.04 -1.63 -0.14
Net Cash From Financing Activities		 305 114 45 120 368 183
Net Cash From Continuing Financing Activities		 305 114 45 120 368 183
Issuance of Debt		 25 25 97 0.00 181 181
Issuance of Common Equity		 191 - 0.00 25 14 0.00
Other Financing Activities, net		 0.00 89 1.94 95 173 1.60
Cash Interest Paid		 1.01 3.46 4.07 7.03 11 17

Quarterly Cash Flow Statements for Phathom Pharmaceuticals

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -11 -41 -26 119 -33 168 -59 -46 58 -37 -85
Net Cash From Operating Activities		 -35 -41 -40 -22 -32 -44 -69 -71 -64 -63 -85
Net Cash From Continuing Operating Activities		 -35 -41 -40 -22 -32 -44 -69 -71 -64 -63 -85
Net Income / (Loss) Continuing Operations		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74 -94
Consolidated Net Income / (Loss)		 -51 -55 -38 -41 -43 -80 -83 -91 -86 -74 -94
Depreciation Expense		 0.18 0.17 0.15 0.12 0.12 0.19 0.21 0.20 0.19 0.19 0.18
Amortization Expense		 0.56 0.50 0.50 0.27 0.54 0.57 0.47 0.50 0.59 0.63 0.70
Non-Cash Adjustments To Reconcile Net Income		 12 13 14 14 14 34 20 21 20 19 17
Changes in Operating Assets and Liabilities, net		 2.91 -0.07 -16 4.38 -3.12 1.29 -7.07 -0.67 1.34 -9.08 -8.95
Net Cash From Investing Activities		 -0.13 -0.41 -0.21 -0.01 -0.94 -0.48 -0.04 -0.05 -0.04 -0.01 -0.02
Net Cash From Continuing Investing Activities		 -0.13 -0.41 -0.21 -0.01 -0.94 -0.48 -0.04 -0.05 -0.04 -0.01 -0.02
Purchase of Property, Plant & Equipment		 -0.13 -0.41 -0.21 -0.01 -0.94 -0.48 -0.04 -0.05 -0.04 -0.01 -0.02
Net Cash From Financing Activities		 25 - 14 142 0.01 212 9.90 25 122 26 0.00
Net Cash From Continuing Financing Activities		 25 - 14 142 0.01 212 9.90 25 122 26 0.00
Issuance of Debt		 - - 0.00 141 - 39 9.90 25 122 25 0.00
Issuance of Common Equity		 25 - 14 0.00 - - 0.00 - - - 0.00
Other Financing Activities, net		 - - - - 0.01 173 0.00 - 0.28 1.30 0.00
Cash Interest Paid		 2.02 2.10 2.55 2.76 2.91 2.91 3.74 4.08 4.66 4.82 5.23

Annual Balance Sheets for Phathom Pharmaceuticals

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 0.90 257 295 189 165 414 378
Total Current Assets		 0.90 256 291 187 161 397 360
Cash & Equivalents		 0.88 244 287 183 155 381 297
Restricted Cash		 - - - - 0.51 2.86 2.86
Accounts Receivable		 - - - - 0.00 1.64 39
Inventories, net		 - - - - 0.00 1.21 3.21
Prepaid Expenses		 0.02 12 3.87 3.27 5.13 13 21
Plant, Property, & Equipment, net		 0.00 0.46 0.99 0.65 1.21 2.15 1.48
Total Noncurrent Assets		 0.00 1.11 2.76 2.26 2.59 11 14
Other Noncurrent Operating Assets		 0.00 1.11 2.76 2.26 2.59 11 14
Total Liabilities & Shareholders' Equity		 0.90 257 295 189 165 414 378
Total Liabilities		 2.19 29 101 117 240 487 632
Total Current Liabilities		 2.19 3.75 56 19 26 39 86
Accounts Payable		 0.06 0.70 17 5.15 10.00 13 11
Accrued Expenses		 0.17 2.32 31 13 15 17 53
Current Deferred Revenue		 - - - - 0.00 7.11 20
Other Current Liabilities		 - 0.57 0.47 0.49 0.71 0.73 0.50
Other Current Nonoperating Liabilities		 0.01 0.16 0.31 0.48 0.85 1.15 1.71
Total Noncurrent Liabilities		 0.00 25 45 98 213 448 546
Long-Term Debt		 0.00 23 40 90 95 138 201
Noncurrent Deferred Revenue		 - - - - 110 300 333
Other Noncurrent Operating Liabilities		 0.00 2.70 5.68 8.68 8.60 10 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.29 228 194 72 -75 -73 -254
Total Preferred & Common Equity		 -1.29 228 194 72 -75 -73 -254
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.29 228 194 72 -75 -73 -254
Common Stock		 0.00 484 580 602 652 856 1,009
Retained Earnings		 -1.29 -256 -385 -529 -727 -929 -1,263
Treasury Stock		 - - - 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for Phathom Pharmaceuticals

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 214 202 144 265 237 356 319 387 294
Total Current Assets		 209 198 140 258 227 340 305 374 265
Cash & Equivalents		 207 197 130 249 214 322 276 335 212
Accounts Receivable		 - - - - - 3.88 11 21 36
Inventories, net		 - - - 0.11 0.11 1.46 2.18 3.11 3.17
Prepaid Expenses		 1.87 0.98 10 8.76 13 13 15 15 13
Plant, Property, & Equipment, net		 0.88 0.83 1.28 1.16 1.98 1.96 1.81 1.66 1.35
Total Noncurrent Assets		 3.36 3.29 2.89 6.16 8.29 11 9.91 8.71 28
Other Noncurrent Operating Assets		 3.36 3.29 2.89 6.16 8.29 11 9.91 8.71 28
Total Liabilities & Shareholders' Equity		 214 202 144 265 237 356 319 387 294
Total Liabilities		 221 228 234 247 255 505 553 574 633
Total Current Liabilities		 21 23 14 22 24 43 47 65 74
Accounts Payable		 5.76 7.14 4.81 4.17 5.79 8.40 7.66 7.13 12
Accrued Expenses		 14 13 8.02 15 14 17 27 36 43
Current Deferred Revenue		 - - - 0.28 2.39 16 9.91 20 17
Other Current Liabilities		 0.63 1.63 0.71 0.72 0.72 0.73 0.72 0.68 0.32
Other Current Nonoperating Liabilities		 0.57 0.69 0.91 0.93 0.96 1.31 1.43 1.52 1.80
Total Noncurrent Liabilities		 199 205 220 226 231 462 506 509 559
Long-Term Debt		 92 94 97 98 99 149 174 176 203
Noncurrent Deferred Revenue		 - - - 120 123 303 321 322 344
Other Noncurrent Operating Liabilities		 107 112 123 8.29 8.13 9.99 11 11 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -7.00 -26 -90 18 -18 -149 -234 -187 -338
Total Preferred & Common Equity		 -7.00 -26 -90 18 -18 -149 -234 -187 -338
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -7.00 -26 -90 18 -18 -149 -234 -187 -338
Common Stock		 614 646 675 823 831 863 869 1,001 1,019
Retained Earnings		 -621 -672 -765 -806 -849 -1,012 -1,103 -1,189 -1,357
Treasury Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Phathom Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 8,001.47%
EBITDA Growth		 0.00% 50.73% -7.29% -27.67% 2.81% -66.31%
EBIT Growth		 0.00% 50.18% -9.20% -25.82% 2.93% -65.66%
NOPAT Growth		 0.00% -18.31% -7.49% -27.66% 2.97% -65.84%
Net Income Growth		 0.00% 49.41% -11.48% -37.42% -1.96% -65.84%
EPS Growth		 0.00% 82.72% -0.26% -29.82% 22.18% -34.61%
Operating Cash Flow Growth		 0.00% -90.87% -113.03% 1.30% 6.11% -93.90%
Free Cash Flow Firm Growth		 0.00% 0.00% -242.32% 94.08% 1,037.16% -343.76%
Invested Capital Growth		 0.00% -744.76% 54.37% -542.26% -136.30% -10.24%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 110.32%
EBITDA Q/Q Growth		 0.00% 0.00% -11.09% -8.74% -16.25% 3.72%
EBIT Q/Q Growth		 0.00% 0.00% -10.87% -8.61% -16.04% 3.65%
NOPAT Q/Q Growth		 0.00% 0.00% -11.04% -8.56% -16.13% 3.63%
Net Income Q/Q Growth		 0.00% 0.00% -11.58% -10.77% -13.85% 1.51%
EPS Q/Q Growth		 0.00% 0.00% 14.32% -8.14% -2.88% 7.84%
Operating Cash Flow Q/Q Growth		 0.00% -7.42% -9.65% 0.15% -2.04% -7.96%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 53.16% 167.46% -1,205.84%
Invested Capital Q/Q Growth		 0.00% 0.00% 35.76% -4.58% -142.34% -0.92%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 75.51% 85.57%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -24,200.59% -496.79%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -24,532.55% -502.18%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -24,560.12% -502.20%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -29,558.94% -605.09%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.23% 102.78% 104.92% 114.59% 120.35% 120.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -225.11% -61.14% -108.01% 14,877.58% 273.21% 204.89%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -57.89% -70.06%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -69.68% -84.41%
Return on Common Equity (ROCE)		 -225.11% -61.14% -108.01% 14,877.58% 273.21% 204.89%
Return on Equity Simple (ROE_SIMPLE)		 -111.92% -66.44% -199.41% 264.29% 277.07% 131.84%
Net Operating Profit after Tax (NOPAT)		 -74 -88 -95 -121 -117 -194
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -17,172.79% -351.53%
Net Nonoperating Expense Percent (NNEP)		 -81.86% -17.83% -29.60% -100.75% -55.39% -81.86%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -179.95% 372.29%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 24.49% 14.43%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 17,291.50% 526.07%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 7,316.57% 61.68%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 24,608.06% 587.75%
Earnings before Interest and Taxes (EBIT)		 -252 -126 -137 -173 -168 -277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -252 -124 -133 -170 -165 -274
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 3.35 4.95 8.56 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.35 4.95 8.56 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 766.45 10.05
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 76.20 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 405.13 8.26
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 4.17 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.10 0.24 1.24 -1.27 -1.89 -0.79
Long-Term Debt to Equity		 0.10 0.20 1.24 -1.27 -1.89 -0.79
Financial Leverage		 -0.97 -1.09 -1.25 57.52 2.07 1.05
Leverage Ratio		 1.14 1.31 1.82 -133.27 -3.92 -2.43
Compound Leverage Factor		 1.15 1.34 1.91 -152.72 -4.72 -2.92
Debt to Total Capital		 9.08% 19.48% 55.41% 465.84% 211.79% -386.06%
Short-Term Debt to Total Capital		 0.00% 3.05% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 9.08% 16.43% 55.41% 465.84% 211.79% -386.06%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 90.92% 80.52% 44.59% -365.84% -111.79% 486.06%
Debt to EBITDA		 -0.09 -0.38 -0.67 -0.56 -0.84 -0.73
Net Debt to EBITDA		 0.88 1.94 0.70 0.36 1.49 0.36
Long-Term Debt to EBITDA		 -0.09 -0.32 -0.67 -0.56 -0.84 -0.73
Debt to NOPAT		 -0.31 -0.53 -0.95 -0.79 -1.18 -1.04
Net Debt to NOPAT		 2.97 2.73 0.99 0.50 2.10 0.51
Long-Term Debt to NOPAT		 -0.31 -0.45 -0.95 -0.79 -1.18 -1.04
Altman Z-Score		 12.23 3.45 -2.08 -7.48 -2.79 -5.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 68.20 5.25 9.86 6.12 10.25 4.20
Quick Ratio		 65.04 5.18 9.69 5.92 9.88 3.92
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -35 -120 -7.08 66 -162
Operating Cash Flow to CapEx		 -27,659.09% -6,700.77% -45,261.28% -14,075.89% -8,419.83% -197,607.41%
Free Cash Flow to Firm to Interest Expense		 0.00 -7.62 -17.61 -0.26 1.58 -2.25
Operating Cash Flow to Interest Expense		 -8.74 -15.21 -21.87 -5.37 -3.28 -3.70
Operating Cash Flow Less CapEx to Interest Expense		 -8.77 -15.44 -21.92 -5.40 -3.32 -3.71
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 2.73
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 3.61
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.41 30.51
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.01 0.69
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 133.56
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 101.08
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 24,695.42 528.94
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -24,695.42 -294.30
Capital & Investment Metrics		 - - - - - -
Invested Capital		 7.12 -46 -21 -135 -318 -351
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.17
Increase / (Decrease) in Invested Capital		 0.00 -53 25 -114 -183 -33
Enterprise Value (EV)		 543 722 524 406 276 457
Market Capitalization		 764 962 618 467 523 555
Book Value per Share		 $9.29 $6.71 $2.30 ($1.80) ($1.27) ($3.71)
Tangible Book Value per Share		 $9.29 $6.71 $2.30 ($1.80) ($1.27) ($3.71)
Total Capital		 251 241 162 20 65 -52
Total Debt		 23 47 90 95 138 201
Total Long-Term Debt		 23 40 90 95 138 201
Net Debt		 -221 -241 -94 -61 -246 -99
Capital Expenditures (CapEx)		 0.13 1.04 0.33 1.04 1.63 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 8.09 -44 -16 -22 -26 -26
Debt-free Net Working Capital (DFNWC)		 252 243 168 134 359 274
Net Working Capital (NWC)		 252 236 168 134 359 274
Net Nonoperating Expense (NNE)		 181 41 49 77 84 140
Net Nonoperating Obligations (NNO)		 -221 -240 -93 -60 -245 -97
Total Depreciation and Amortization (D&A)		 0.42 1.60 4.12 2.73 2.45 2.99
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -3,754.40% -46.55%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 52,588.12% 496.64%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 52,588.12% 496.64%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.89) ($5.05) $0.00 ($5.29)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 31.71M 39.12M 0.00 63.18M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.89) ($5.05) $0.00 ($5.29)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 31.71M 39.12M 0.00 63.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($3.89) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 37.00M 41.97M 0.00 69.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -74 -88 -95 -121 -117 -194
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -17,172.79% -351.53%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -29,558.94% -605.09%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -60.34 -27.41 -20.20 -6.32 -3.99 -3.85
NOPAT to Interest Expense		 -17.80 -19.20 -13.93 -4.42 -2.79 -2.70
EBIT Less CapEx to Interest Expense		 -60.37 -27.64 -20.25 -6.36 -4.03 -3.86
NOPAT Less CapEx to Interest Expense		 -17.83 -19.43 -13.98 -4.46 -2.83 -2.70
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Phathom Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,249.56% 1,391.58%
EBITDA Growth		 -27.97% -42.12% 21.07% 29.95% 15.81% -50.08% -135.62% -144.74% -98.97% 15.32% -12.56%
EBIT Growth		 -20.90% -41.37% 20.72% 30.13% 15.71% -49.55% -132.88% -143.88% -97.47% 15.05% -12.70%
NOPAT Growth		 -28.34% -41.17% 20.65% 30.12% 16.15% -49.81% -132.58% -143.84% -98.54% 14.97% -12.74%
Net Income Growth		 -39.36% -53.65% 7.01% 19.55% 15.36% -44.55% -119.10% -123.23% -97.90% 6.43% -13.84%
EPS Growth		 -34.69% -40.00% 16.82% 36.84% 42.42% -8.27% -59.55% -85.71% -73.68% 31.25% 7.75%
Operating Cash Flow Growth		 -20.47% 0.54% 11.37% 13.67% 8.86% -6.72% -73.99% -218.56% -99.20% -44.89% -23.05%
Free Cash Flow Firm Growth		 586.46% 268.36% 310.67% -118.43% -133.82% 66.12% 64.18% 1,458.93% 842.99% -106.72% -121.59%
Invested Capital Growth		 -294.56% -542.26% -1,331.65% -9.16% -1.97% -136.30% -164.50% -154.37% -164.72% -10.24% -6.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 180.35% 283.05% 123.27% 81.41% -3.86%
EBITDA Q/Q Growth		 6.45% -10.21% 36.15% -6.42% -12.43% -96.45% -0.25% -10.53% 8.60% 16.39% -33.25%
EBIT Q/Q Growth		 6.23% -9.85% 35.68% -5.46% -13.12% -94.92% -0.15% -10.44% 8.41% 16.15% -32.87%
NOPAT Q/Q Growth		 6.25% -9.67% 35.52% -5.40% -12.49% -95.95% -0.11% -10.50% 8.41% 16.07% -32.73%
Net Income Q/Q Growth		 -0.34% -7.74% 31.31% -8.33% -5.56% -84.01% -4.12% -10.37% 6.42% 13.00% -26.68%
EPS Q/Q Growth		 0.75% -0.76% 33.08% 5.62% 9.52% -89.47% 1.39% -9.86% 15.38% 25.00% -32.32%
Operating Cash Flow Q/Q Growth		 -36.16% -17.21% 3.34% 44.04% -43.76% -37.23% -57.59% -2.46% 10.11% 0.18% -33.84%
Free Cash Flow Firm Q/Q Growth		 10.35% 22.13% 14.38% -111.95% -102.54% 699.92% 13.05% -1.07% 10.74% -105.42% -263.41%
Invested Capital Q/Q Growth		 -6.02% -4.58% 9.19% -8.42% 0.97% -142.34% -1.65% -4.27% -3.06% -0.92% 1.41%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 75.51% 77.72% 81.21% 85.59% 87.14% 86.94%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,137.54% -3,624.95% -1,046.00% -428.23% -197.36% -273.54%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,245.60% -3,658.68% -1,055.43% -432.95% -200.30% -276.53%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,247.65% -3,660.93% -1,055.52% -433.00% -200.13% -276.61%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -11,667.16% -4,333.26% -1,248.58% -523.34% -250.98% -330.71%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 120.10% 117.79% 125.81% 129.24% 120.60% 113.85% 118.37% 118.29% 120.86% 125.41% 119.56%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -463.29% 14,877.58% 747.21% -3,489.00% 801.29% 273.21% 206.65% 274.81% 331.35% 204.89% 142.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -24.16% -37.95% -35.83% -36.46% -27.92% -69.59%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -27.50% -44.92% -42.38% -44.06% -35.01% -83.21%
Return on Common Equity (ROCE)		 -463.29% 14,877.58% 747.21% -3,489.00% 801.29% 273.21% 206.65% 274.81% 331.35% 204.89% 142.04%
Return on Equity Simple (ROE_SIMPLE)		 675.56% 0.00% 216.06% -1,050.66% 996.28% 0.00% 166.08% 127.06% 181.41% 0.00% 102.19%
Net Operating Profit after Tax (NOPAT)		 -30 -33 -21 -22 -25 -49 -49 -54 -50 -42 -55
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -7,171.92% -2,561.08% -738.80% -303.07% -140.21% -193.57%
Net Nonoperating Expense Percent (NNEP)		 -17.89% -29.30% -42.65% -14.20% -16.95% -20.10% -32.77% -29.47% -26.32% -19.20% -42.97%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -75.15% - - - 79.72% 40.85%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 24.49% 22.28% 18.79% 14.41% 12.86% 13.06%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 8,357.33% 3,243.20% 1,035.94% 465.38% 258.51% 331.27%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,963.78% 493.20% 100.71% 53.16% 28.93% 32.20%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 10,321.11% 3,736.40% 1,136.65% 518.54% 287.44% 363.47%
Earnings before Interest and Taxes (EBIT)		 -43 -47 -30 -32 -36 -70 -70 -77 -71 -59 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -46 -29 -31 -35 -69 -69 -77 -70 -59 -78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 35.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 35.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 766.45 239.41 60.73 41.01 10.05 5.33
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 405.13 171.53 50.18 34.86 8.26 5.22
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 4.17 7.94 18.02 62.63 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -3.55 -1.27 -1.07 5.56 -5.58 -1.89 -1.00 -0.75 -0.94 -0.79 -0.60
Long-Term Debt to Equity		 -3.55 -1.27 -1.07 5.56 -5.58 -1.89 -1.00 -0.75 -0.94 -0.79 -0.60
Financial Leverage		 -3.09 57.52 1.51 -24.95 4.88 2.07 0.87 1.17 1.34 1.05 0.37
Leverage Ratio		 5.58 -133.27 -5.62 45.15 -9.93 -3.92 -2.10 -2.70 -3.05 -2.43 -1.34
Compound Leverage Factor		 6.71 -156.99 -7.07 58.34 -11.98 -4.46 -2.48 -3.20 -3.68 -3.04 -1.60
Debt to Total Capital		 139.17% 465.84% 1,499.89% 84.75% 121.81% 211.79% 28,658.27% -293.61% -1,543.78% -386.06% -150.41%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 139.17% 465.84% 1,499.89% 84.75% 121.81% 211.79% 28,658.27% -293.61% -1,543.78% -386.06% -150.41%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -39.17% -365.84% -1,399.89% 15.25% -21.81% -111.79% -28,558.27% 393.61% 1,643.78% 486.06% 250.41%
Debt to EBITDA		 -0.60 -0.56 -0.60 -0.66 -0.70 -0.84 -0.73 -0.70 -0.62 -0.73 -0.72
Net Debt to EBITDA		 0.66 0.36 0.20 1.02 0.81 1.49 0.86 0.42 0.57 0.36 0.03
Long-Term Debt to EBITDA		 -0.60 -0.56 -0.60 -0.66 -0.70 -0.84 -0.73 -0.70 -0.62 -0.73 -0.72
Debt to NOPAT		 -0.84 -0.79 -0.84 -0.93 -0.98 -1.18 -1.03 -0.99 -0.87 -1.04 -1.01
Net Debt to NOPAT		 0.93 0.50 0.29 1.43 1.13 2.10 1.21 0.59 0.80 0.51 0.05
Long-Term Debt to NOPAT		 -0.84 -0.79 -0.84 -0.93 -0.98 -1.18 -1.03 -0.99 -0.87 -1.04 -1.01
Altman Z-Score		 -3.17 -4.97 -6.31 -2.07 -3.10 -2.01 -2.88 -3.98 -2.75 -3.65 -5.87
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.65 6.12 9.68 11.96 9.46 10.25 7.83 6.48 5.73 4.20 3.58
Quick Ratio		 8.60 5.92 8.97 11.55 8.91 9.88 7.50 6.11 5.45 3.92 3.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 66 81 93 -11 -22 135 152 150 167 -9.03 -33
Operating Cash Flow to CapEx		 -26,131.34% -9,961.41% -18,536.92% -370,000.00% -3,398.72% -9,220.42% -172,550.00% -153,741.30% -144,484.09% -1,269,120.00% -471,833.33%
Free Cash Flow to Firm to Interest Expense		 7.15 8.43 10.05 -1.15 -2.22 10.33 8.86 8.47 9.01 -0.49 -1.82
Operating Cash Flow to Interest Expense		 -3.77 -4.27 -4.30 -2.31 -3.16 -3.36 -4.02 -3.98 -3.44 -3.41 -4.70
Operating Cash Flow Less CapEx to Interest Expense		 -3.79 -4.32 -4.33 -2.31 -3.25 -3.40 -4.02 -3.98 -3.44 -3.41 -4.70
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.08 0.14 0.25
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.73 4.07
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.72 2.68 3.61 4.88
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.41 1.60 6.68 14.47 30.51 49.37
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.09 0.33 0.67 0.69 1.13
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 133.56 89.72
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 212.07 135.96 101.08 74.87
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 24,695.42 4,064.86 1,096.48 545.47 528.94 324.16
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -24,695.42 -4,064.86 -884.42 -409.52 -294.30 -159.57
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -129 -135 -122 -133 -131 -318 -323 -337 -347 -351 -346
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.04 -0.11 -0.17 -0.24
Increase / (Decrease) in Invested Capital		 -96 -114 -114 -11 -2.54 -183 -201 -205 -216 -33 -22
Enterprise Value (EV)		 331 406 267 474 475 276 445 498 916 457 428
Market Capitalization		 434 467 300 625 589 523 621 602 1,077 555 437
Book Value per Share		 ($0.67) ($1.80) ($2.15) $0.40 ($0.31) ($1.27) ($2.54) ($4.00) ($3.14) ($3.71) ($4.86)
Tangible Book Value per Share		 ($0.67) ($1.80) ($2.15) $0.40 ($0.31) ($1.27) ($2.54) ($4.00) ($3.14) ($3.71) ($4.86)
Total Capital		 67 20 6.44 115 81 65 0.52 -59 -11 -52 -135
Total Debt		 94 95 97 98 99 138 149 174 176 201 203
Total Long-Term Debt		 94 95 97 98 99 138 149 174 176 201 203
Net Debt		 -103 -61 -33 -151 -114 -246 -176 -105 -162 -99 -9.07
Capital Expenditures (CapEx)		 0.13 0.41 0.21 0.01 0.94 0.48 0.04 0.05 0.04 0.01 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -22 -22 -4.17 -13 -11 -26 -28 -21 -29 -26 -21
Debt-free Net Working Capital (DFNWC)		 175 134 125 236 203 359 297 258 309 274 191
Net Working Capital (NWC)		 175 134 125 236 203 359 297 258 309 274 191
Net Nonoperating Expense (NNE)		 21 22 17 19 18 31 34 37 36 33 39
Net Nonoperating Obligations (NNO)		 -102 -60 -32 -150 -113 -245 -175 -103 -160 -97 -7.27
Total Depreciation and Amortization (D&A)		 0.74 0.67 0.64 0.40 0.66 0.75 0.69 0.70 0.78 0.82 0.87
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -3,754.40% -1,088.70% -214.97% -110.42% -46.55% -26.20%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 52,588.12% 11,443.91% 2,599.10% 1,174.47% 496.64% 233.17%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 52,588.12% 11,443.91% 2,599.10% 1,174.47% 496.64% 233.17%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99) ($1.31)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M 71.97M
Adjusted Diluted Earnings per Share		 $0.00 ($1.33) ($0.89) ($0.84) ($0.76) ($1.44) ($1.42) ($1.56) ($1.32) ($0.99) ($1.31)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 39.12M 42.35M 48.50M 56.78M 51.29M 58.37M 58.56M 64.63M 63.18M 71.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 41.97M 43.61M 56.80M 57.25M 58.48M 58.54M 59.59M 68.38M 69.64M 69.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -33 -21 -22 -25 -49 -49 -54 -50 -42 -55
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -7,171.92% -2,561.08% -738.80% -303.07% -140.21% -193.57%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -11,667.16% -4,333.26% -1,248.58% -523.34% -250.98% -330.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.59 -4.87 -3.26 -3.30 -3.55 -5.36 -4.08 -4.35 -3.83 -3.19 -4.37
NOPAT to Interest Expense		 -3.21 -3.40 -2.28 -2.31 -2.47 -3.75 -2.85 -3.05 -2.68 -2.24 -3.05
EBIT Less CapEx to Interest Expense		 -4.60 -4.91 -3.28 -3.30 -3.64 -5.40 -4.08 -4.35 -3.83 -3.19 -4.37
NOPAT Less CapEx to Interest Expense		 -3.22 -3.44 -2.31 -2.31 -2.56 -3.79 -2.85 -3.05 -2.68 -2.24 -3.06
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Phathom Pharmaceuticals posted Q1 2025 revenue of $28.52 million, representing 13.9% YoY growth, but operating losses and cash burn intensified. The company remains well‐capitalized with a net cash position yet faces widening net losses and negative free cash flow as it continues investing in commercialization and R&D.

  • Cash & equivalents of $212.3 M and net debt of -$9.07 M; strong liquidity (current ratio 3.58x)
  • Revenue of $28.52 M, up 13.9% year-over-year
  • Deferred revenue of $343.8 M supports future revenue recognition
  • R&D was 0.32% of revenue and SG&A 3.31%, reflecting continued pipeline investment
  • Net loss widened to $94.32 M (net margin -3.31%) vs. $74.45 M in Q4 2024
  • Free cash flow to firm was -$32.83 M and operating cash flow -$84.93 M, highlighting ongoing cash burn
  • Interest expense rose to $18.07 M, further pressuring pre-tax income
  • Negative EBITDA of -$78.01 M (margin -2.74%) vs. -$58.55 M prior quarter
  • Altman Z-Score of -5.87 indicates elevated financial distress risk
  • Total liabilities of $632.6 M far exceed negative equity of -$338.4 M
06/27/25 11:48 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Phathom Pharmaceuticals' Financials

When does Phathom Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Phathom Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Phathom Pharmaceuticals' net income changed over the last 5 years?

Phathom Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$334.33 million in 2024, rising from -$255.13 million in 2019. The previous period was -$201.59 million in 2023. View Phathom Pharmaceuticals' forecast to see where analysts expect Phathom Pharmaceuticals to go next.

What is Phathom Pharmaceuticals' operating income?
Phathom Pharmaceuticals' total operating income in 2024 was -$277.47 million, based on the following breakdown:
  • Total Gross Profit: $47.28 million
  • Total Operating Expenses: $324.75 million
How has Phathom Pharmaceuticals' revenue changed over the last 5 years?

Over the last 5 years, Phathom Pharmaceuticals' total revenue changed from $0.00 in 2019 to $55.25 million in 2024, a change of 5,525,200,000.0%.

How much debt does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals' total liabilities were at $631.90 million at the end of 2024, a 29.9% increase from 2023, and a 28,780.2% increase since 2018.

How much cash does Phathom Pharmaceuticals have?

In the past 6 years, Phathom Pharmaceuticals' cash and equivalents has ranged from $879 thousand in 2018 to $381.39 million in 2023, and is currently $297.26 million as of their latest financial filing in 2024.

How has Phathom Pharmaceuticals' book value per share changed over the last 5 years?

Over the last 5 years, Phathom Pharmaceuticals' book value per share changed from 9.29 in 2019 to -3.71 in 2024, a change of -139.9%.


Related Companies

This page (NASDAQ:PHAT) was last updated on 6/27/2025 by MarketBeat.com Staff
From Our Partners
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...
Weiss Ratings | Sponsored
The $15 Gold Fund That Pays Up to $1,152/Month
Gold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...
Investors Alley | Sponsored